Phathom Pharmaceuticals (stock symbol: PHAT) Logo in transparent PNG format

Phathom Pharmaceuticals Logo large

Phathom Pharmaceuticals Logo icon format

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

  • Website domain: phathompharma.com
  • Employees: 77
  • Marketcap: $0.42 Billion USD

Page last updated on:

October 23rd, 2020

Categories: